100 Sovereign Drive,
Route 21 Corporate Park,
Nellmapius Drive, Irene 0157,
Pretoria, South Africa
About Clinigen South Africa
Headquartered in Pretoria, Clinigen South Africa, provides healthcare professionals in South Africa with access to a range of both propriety and in-licensed products, meeting increasing demand for hospital based oncology, anti-infective, orphan and other crucial drugs in emerging markets, including:
- Named Patient Supply
- Exclusive Early Access Program
- Niche Pharmaceuticals
- Generic Pharmaceuticals
- Medical Devices
With over 100 staff in South Africa, 1 in Kenya and 50+ in Sales and Marketing, Clinigen SA infrastructure enables the effective product lifecycle management of existing registered products, management of import and supply in Southern Africa and warehousing and logistics capabilities for distribution throughout South Africa, as well as expanding into the rest of Africa.
Clinigen SA is committed to building lasting relationships with blue chip pharmaceutical and medical technology companies throughout the world and providing hospital pharmacists throughout the region with the medicines they need. Clinigen SA’s underlying philosophy is getting the right medicine to the right patient in the quickest possible time, no matter the location.
The South African entity consists of five operational companies that provide a variety of products and services. The four companies are, Equity Pharmaceuticals, Novagen Pharma, Homemed, Equity Medical Technologies and Equipharm Specialised Distribution.
Equity Pharmaceuticals was originally established in 1995 as a research and development company and later in 2007 changed to providing healthcare professionals in South Africa with access to a range of essential medicines, meeting demand for an expanding mix of medical needs in a variety of therapeutic areas. The Holding Company (Equity Pharma Holdings) in 2010, merged with Link Medical Products to form the Link Group, expanding the Group’s reach with the AAA region. The Link Group was acquired by the Clinigen Group in 2015, significantly strengthening Clinigen’s global presence. With this acquisition, Clinigen became the global leader in providing ethical, compliant access to unlicensed medicines and expanded its capability to provide access to medicines for patients in the AAA (Africa, Australasia and Asia) region.